Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

583
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
583

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Viscoelastic Testing for the Laboratorian: Recent Advances and Practical Advice.

Clinics in laboratory medicine·2026
Same author

Lung transplantation in recipients aged ≥70 years: a single-center experience.

JHLT open·2026
Same author

D-Dimer Reporting and Harmonization: Analysis of College of American Pathologists D-Dimer Proficiency Testing Program.

Seminars in thrombosis and hemostasis·2026
Same author

Viscoelastic Testing to Guide Anticoagulation During Extracorporeal Membrane Oxygenation in Lung Transplantation.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

Bilateral lung herniation with parenchymal infarction following clamshell thoracotomy for lobar lung transplantation: a case report.

Journal of cardiothoracic surgery·2025
Same author

Lobar lung transplantation, followed by partial sternal resection and bronchial stenosis, in a patient with scoliosis.

Journal of cardiothoracic surgery·2025

相关实验视频

Updated: Jan 1, 2026

Point-of-Care Ultrasound for Peripheral Veno-Arterial Extracorporeal Membrane Oxygenation Without Left Ventricular Venting
03:40

Point-of-Care Ultrasound for Peripheral Veno-Arterial Extracorporeal Membrane Oxygenation Without Left Ventricular Venting

Published on: January 17, 2025

701

在ECMO期间的抗凝管理:叙事审查

Jaromir Vajter1, Oksana Volod2

  • 1Department of Anaesthesiology, Resuscitation, and Intensive Care Medicine, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Czech Republic.

JHLT open
|March 27, 2025
PubMed
概括

在体外膜氧化 (ECMO) 过程中管理抗凝剂对于预防凝块和出血至关重要. 目前的做法涉及未分离的肝素,新兴的工具,如粘弹性测试提供了更好的监测,以获得更好的患者结果.

关键词:
这是一种抗凝血药物.阿尔加特罗班 (阿尔加特罗班)比瓦利鲁丁 (Bivalirudin) 是一种生物.在ECMO中,可以使用ECMO.在LMWH中使用LMWH.在UFH中,UFH是UFH.

更多相关视频

Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death
09:54

Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death

Published on: August 15, 2022

2.2K
Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse
06:41

Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse

Published on: October 24, 2018

12.9K

相关实验视频

Last Updated: Jan 1, 2026

Point-of-Care Ultrasound for Peripheral Veno-Arterial Extracorporeal Membrane Oxygenation Without Left Ventricular Venting
03:40

Point-of-Care Ultrasound for Peripheral Veno-Arterial Extracorporeal Membrane Oxygenation Without Left Ventricular Venting

Published on: January 17, 2025

701
Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death
09:54

Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death

Published on: August 15, 2022

2.2K
Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse
06:41

Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse

Published on: October 24, 2018

12.9K

科学领域:

  • 心脏病学 心脏病学
  • 血液学 血液学 血液学
  • 关键护理医学 关键护理医学

背景情况:

  • 身体外膜氧化 (ECMO) 是严重心肺衰竭的救生疗法.
  • 有效的抗凝剂对于预防ECMO期间危及生命的血栓栓塞事件至关重要.
  • 由于凝血病和出血风险,管理ECMO患者的抗凝血药物存在独特的挑战.

研究的目的:

  • 审查目前在ECMO中使用的抗凝固策略,药物和监测技术.
  • 讨论ECMO抗凝固管理中的挑战和新兴见解.
  • 强调个性化方法和先进监测对于优化ECMO治疗的重要性.

主要方法:

  • 对ECMO中抗凝实践的当前文献的综述.
  • 分析常用的抗凝剂,包括未分离的肝素,LMWH和直接的血栓抑制剂.
  • 评估监测方法,如aPTT,ACT,抗Xa测定和粘弹性测定 (VEA).

主要成果:

  • 不分离的肝素 (UFH) 是标准,由aPTT或ACT监测,越来越多地使用抗Xa和VEA以提高准确性.
  • 当水平下降到50%-70%以下时,建议补充抗血素,以提高肝素的疗效.
  • 像比瓦利鲁丁这样的直接血栓激素抑制剂是氨酸诱导的血栓缩的替代品,尽管存在成本和可用性问题.

结论:

  • 在ECMO中进行抗凝管理是复杂的,需要在血栓形成和出血风险之间保持平衡.
  • 个性化协议和护理点VEA正在成为有效ECMO抗凝药的关键工具.
  • 标准化方案和正在进行的研究对于优化抗凝药和改善高风险ECMO患者的治疗结果至关重要.